CleanSlate Stock

cleanslatecenters.comHealthcareFounded: 1900Funding to Date: $79.02MM

CleanSlate is a national medical group that provides treatment for the chronic disease of addiction using an integrated approach combining medication-assisted treatment, primary care services and behavioral health therapies to treat polysubstance use disorder and associated co-occurring disorders.

Register for Details

For more details on financing and valuation for CleanSlate, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for CleanSlate.

Register Today


Management Team

Anthony Belott
Chief Development Officer
Paul Chabot
Chief Information Officer
Robert Hutchison
Chief Financial Officer
Gregory Marotta
President, Board Member & Chief Executive Officer
Bob Wilson
Chief Human Resources Officer
Amanda Wilson MD
Founder & Chairwoman
Adam McPhee
Chief Operating Officer
Neil Kunkel JD
Chief Legal Officer
Tracey Cohen MD
Chief Clinical Officer

Board Members

Christopher Jedrey Ph.D
Jared Teo
HealthQuest Capital
Paul Brown JD
Eugene Fleming
Garheng Kong MD
HealthQuest Capital
Patrick Kennedy
Diane Daych
Granite Growth Health Partners
Mark Brooks
Granite Growth Health Partners
Amanda Wilson MD

Other companies like CleanSlate in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


A substance abuse treatment company and its former owner, Dr. Amanda L. Wilson, wrongly charged MassHealth millions of dollars for urine tests patients did not need, Attorney General Maura Healey alleges in a new federal lawsuit.
CleanSlate UV, a Toronto, Canada and Buffalo, NY-based infection control startup offering a hospital-grade, chemical-free sanitizer for mobile devices, raised US$7m in initial close of a new financing round
National leader in outpatient pharmacological treatment for the chronic disease of addiction announces $25 million in financing to accelerate growth.